NHS England, NHS Improvement 12 September 2017
- Biological medicines are currently the largest cost and cost growth areas in the NHS medicines budget. Many biological medicines are coming off patent and “biosimilars” are becoming available. Using a new commissioning framework, NHS England aims to drive a step change in the uptake of biosimilar medicines by CCGs and providers.
- The report outlines the opportunities for use of biosimilars for a number of currently used biologicals and a link to the Medicines Optimisation Dashboard which gives details of use of Infliximab and Etanercept by provider and CCG.
- Background and developments on the NHS England Biosimilar Medicine webpage.
